Clinical trials: Bortezomib
Multiple Myeloma
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, and dose regimen of daratumumab when administered in combination with various treatment regimens for the treatment of multiple myeloma.
- Trial name
- NCT01998971
- Testing
- Daratumumab, Velcade, Pomalidomide
- Where
- 22 sites in United States, France and 1 more
- Volunteers
- 240 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, Peripheral Neuropathy
Skin Biopsies in Chemotherapy-Induced Neuropathy
Neuropathy is a common side effect of chemotherapeutics used for the treatment of multiple myeloma, including vincristine, thalidomide and bortezomib. The neuropathy induced by these drugs is often preferentially small fiber.
- Trial name
- NCT00956033
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Erasmus Medical Center
Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00027898
- Testing
- bortezomib, carboplatin, etoposide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib
H9S-MC-JDCF was a multicenter non-randomized, single-arm, open-label, dose-escalation, dose confirmation, Phase 1 study of intravenous (IV) LY2127399 in combination with bortezomib in patients with refractory or relapsed MM.
- Trial name
- NCT00689507
- Testing
- LY2127399
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Applied Molecular Evolution
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
This phase II trial is studying how well giving bortezomib together with paclitaxel and carboplatin works in treating patients with metastatic melanoma.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Recurrent Intraocular Melanoma
- Trial name
- NCT00288041
- Testing
- carboplatin, paclitaxel, bortezomib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Neuromyelitis Optica Spectrum Disorder
Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
Neuromyelitis Optica Spectrum Disorders (NMOSD) is characterized by the pathogenic anti-AQP4 antibody, which can be produced by specific plasma cells.
- Trial name
- NCT02893111
- Testing
- Bortezomib
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Tianjin Medical University General Hospital
Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation
Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study
Despite the advantages of autologous stem cell transplantation (ASCT) over conventional chemotherapy,1,2 the results of high-dose chemoradiotherapy in multiple myeloma (MM) are still unsatisfactory with a 6-year event free…
- Trial name
- NCT01255527
- Testing
- Bortezomib
- Where
- 8 sites in South Korea
- Volunteers
- 53 people
- Sponsor
- Yonsei University
Amyloidosis
Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis
This is a phase 1/2 open-label, dose-escalation study investigating single-agent therapy with VELCADE in patients with previously treated systemic AL-amyloidosis who require further treatment.
- Trial name
- NCT00298766
- Testing
- VELCADE
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
The combination of PARP inhibitor (ABT-888) with a proteasome inhibitors (bortezomib) have demonstrated significant anti-myeloma effects in preclinical lab and animal studies.
- Trial name
- NCT01495351
- Testing
- ABT-888/Bortezomib
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- AHS Cancer Control Alberta
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
This phase I trial is studying the side effects and best dose of tipifarnib and bortezomib in treating patients with acute leukemia or chronic myelogenous leukemia in blast phase.
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
- Trial name
- NCT00383474
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Tipifarnib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
This study aims to monitor patients for relapse of the leukemia following allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in order to identify patients early in relapse, with a low burden of disease, when interventions…
- Trial name
- NCT02484261
- Testing
- Bortezomib, Pravastatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Reuven Schore
Multiple Myeloma, Amyloidosis
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple…
- Trial name
- NCT04991103
- Testing
- DaraVRD/DaraVCD
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Mantle Cell Lymphoma
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
This is a Phase I/II multicenter, open-label, dose-escalation study of rituximab, bortezomib, and lenalidomide in the first-line or second-line treatment of patients with Mantle Cell Lymphoma (MCL).
- Trial name
- NCT00633594
- Testing
- Rituximab, Bortezomib, Lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- SCRI Development Innovations, LLC
Multiple Myeloma
Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure
Primary outcome measure: Analyze the efficacy (in order to evaluate the response) of Bortezomib/Dexamethasone treatment Secondary outcome measures: Study the speed of response and the response rate (M component in serum and urine…
- Trial name
- RENVEL (NCT01084837)
- Testing
- velcade
- Where
- 11 sites in Spain
- Volunteers
- 60 people
- Sponsor
- PETHEMA Foundation
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
This phase II trial is studying how well bortezomib works in treating patients with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00077441
- Testing
- bortezomib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib
This study will observe the degree of the quality of life in non-transplant candidate patients with multiple myeloma before and after bortezomib administration by using EORTC-QLQ C30 (European Organization for Research and…
- Trial name
- NCT01060202
- Testing
- No intervention
- Volunteers
- 60 people
- Sponsor
- Janssen Korea, Ltd., Korea
Chronic Graft-versus-host Disease
Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)
The purpose of this study is to see if bortezomib (Velcade) is effective in the treatment of refractory cGVHD.
- Trial name
- NCT01158105
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Baylor Research Institute
Graft Versus Host Disease
Bortezomib in Patients With Chronic Graft Versus Host Disease
This study will investigate whether bortezomib can control the immune system and can be used to treat GVHD. Bortezomib has been used with not too many serious side effects in patients with multiple myeloma who will undergo…
- Trial name
- NCT01672229
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mehrdad Abedi, MD
Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial studies how well bortezomib and vorinostat work in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00703664
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Vorinostat
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.
- Trial name
- NCT00560352
- Testing
- Dasatinib, Bortezomib, Dexamethasone
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb